Europe Thalassemia Market Insights Forecasts to 2033

• The Europe Thalassemia Market Size was valued at USD 187.2 Million in 2023.
• The Market Size is Growing at a CAGR of 7.55% from 2023 to 2033
• The Europe Thalassemia Market Size is Expected to Reach USD 387.6 Million by 2033

The Europe Thalassemia Market Size is Anticipated to Reach USD 387.6 Million by 2033, Growing at a CAGR of 7.55% from 2023 to 2033.

Market Overview

Thalassemia is a blood disorder that occurs when the body doesn't produce enough hemoglobin, a protein found in red blood cells that carries oxygen. It is an inherited blood disorder that causes the body to produce an abnormal amount or form of hemoglobin. Thalassemia is caused by a defect in a gene that controls the production of alpha or beta globin, the two proteins that make up hemoglobin. It's also possible to be a carrier of thalassemia. Moreover, In Europe, the prevalence of thalassemia is estimated to be 1 in 10,000 people. It is more common in some countries, such as Italy, Greece, and Cyprus, and less common in others, such as Germany, the Netherlands, Belgium, and the Nordics. Additionally, the increasing population, especially in countries where there is a high prevalence of thalassemia contributes to the rising number of thalassemia patients. Therefore, the rising prevalence of thalassemia will drive the Europe thalassemia treatment market’s growth.

Report Coverage

This research report categorizes the market for the Europe thalassemia market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Europe thalassemia market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Europe thalassemia market.

Driving Factors

The thalassemia market in Europe is expected to grow due to several factors. These include the increasing number of people with thalassemia, the development and approval of new treatments, such as the authorization of Casgevy, a gene-editing therapy for beta-thalassemia by the Medicines and Healthcare Products Regulatory Agency (MHRA) in 2023, the rise in healthcare spending, increasing awareness programs, and the support and funding provided by governments for thalassemia. Other contributing factors to the growth of the thalassemia market may include medical advancements, a rising number of older people, changing lifestyles, more people undergoing genetic testing early, and an increase in the number of people seeking genetic counseling.

Restraining Factors

Thalassemia is a rare genetic disorder that necessitates costly treatments and therapies. The main treatment involves blood transfusions, which are expensive due to the frequency of transfusions and the complexities of obtaining blood. Additional costs include medications, hospital services, staff, and long-term care. Advanced treatments such as gene therapy or bone marrow transplants are even more expensive. Side effects associated with thalassemia therapy can hinder the European market. In low- and middle-income countries, where most thalassemia cases occur, healthcare infrastructure and coverage are inadequate.

Market Segmentation

The Europe thalassemia market share is classified into treatment and type.

• The iron chelating drugs segment is expected to hold the largest market share through the forecast period.

The Europe thalassemia market is segmented by treatment into iron chelating drugs, erythyroid maturation agents, stem cell therapy, and others. Among these, the iron-chelating drugs segment is expected to hold the largest market share through the forecast period. Patients with thalassemia often need regular blood transfusions, which can result in iron overload in the body. Iron overload can lead to severe complications, including organ damage and heart problems. Iron-chelating drugs are crucial for managing iron overload as they bind excess iron and help the body excrete it.

• The beta thalassemia segment is expected to dominate the Europe thalassemia market during the forecast period.

Based on the type, the Europe thalassemia market is divided into alpha thalassemia and beta thalassemia. Among these, the beta thalassemia segment is expected to dominate the Europe thalassemia market during the forecast period. The ongoing advances in diagnostic techniques and treatment options for beta thalassemia have greatly improved patient outcomes. Additionally, innovations such as genetic testing, prenatal screening, and stem cell transplantation have enhanced early detection and management strategies for beta-thalassemia patients. This has led to an increased demand for healthcare services and products related to beta-thalassemia.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Europe thalassemia market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc.,
• FRESENIUS SE & Co. KGaA (Fresenius Kabi)
• Bristol Myers Squibb Co.
• Chiesi Farmaceutici S.p.A
• Apotex Inc
• Novartis AG
• Alvogen Inc
• Bluebirdbio
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In February 2024, The European Commission approved the CRISPR Therapeutics and Vertex Pharmaceuticals' exabreed gene therapy for the treatment of patients 12 years and older with severe sickle cell disease (SCD) characterized by recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta-thalassemia (TDT). This treatment is suitable for patients for whom hematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen-matched related HSC donor is not available.

Market Segment

This study forecasts revenue at Europe, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Europe Thalassemia Market based on the below-mentioned segments:

Europe Thalassemia Market, By Treatment

• Iron Chelating Drugs
• Erythyroid maturation agents
• Stem Cell therapy
• Others

Europe Thalassemia Market, By Type

• Alpha Thalassemia
• Beta Thalassemia